• Explore /
  • Poster
  • / Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study.

Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study.

Abstract Poster

Authors

null

Ronan Flippot

Department of Medical Oncology, Gustave Roussy, Villejuif, France

Ronan Flippot , Tugce Telli , Maud Velev , Aude Flechon , Lea Turpin , Andre M. Bergman , Fabio Turco , Wolfgang Peter Fendler , Anne Laure Giraudet , Françoise Montravers , Wouter V. Vogel , Silke Gillessen , Simona Berardi , Ken Herrmann , David Kryza , Gaetano Paone , Camilo Garcia , Stéphanie Foulon , Arnaud Pages , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 180)

DOI

10.1200/JCO.2023.41.6_suppl.180

Abstract #

180

Poster Bd #

F17

Abstract Disclosures

Similar Posters

First Author: Daniel Peter Petrylak

Poster

2019 Genitourinary Cancers Symposium

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Edmond Michael Kwan

First Author: Daniel Peter Petrylak

First Author: Umang Swami